IBRX is trading 10.9% up today at $8.01 as investors react to the May 26, 2026, lead-plaintiff deadline for multiple securities class actions tied to Anktiva disclosures.
- The move follows weeks of downward pressure triggered by an FDA warning letter and subsequent lawsuit headlines.
- Market participants appear to be positioning around the perceived legal overhang and short-term sentiment rather than any new fundamental updates to the company's drug pipeline.